Analysis of IL-10, IL-4 and TNF-alpha polymorphisms in drug-induced liver injury (DILI) and its outcome.

[1]  E. Björnsson,et al.  The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug‐induced liver injury , 2007, Alimentary pharmacology & therapeutics.

[2]  F. Ruiz-Cabello,et al.  Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug‐induced idiosyncratic liver injury (DILI) , 2007, British journal of pharmacology.

[3]  P. Meier,et al.  Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury , 2007, Pharmacogenetics and genomics.

[4]  A. Iolascon,et al.  Interleukin-10 - 1082 GG polymorphism influences the occurrence and the clinical characteristics of hepatitis C virus infection. , 2006, Journal of hepatology.

[5]  G. Sitia,et al.  Reduced severity of liver ischemia/reperfusion injury following hepatic resection in humans is associated with enhanced intrahepatic expression of Th2 cytokines. , 2006, Hepatology research : the official journal of the Japan Society of Hepatology.

[6]  G. Sesti,et al.  Variants of the Interleukin-10 Promoter Gene Are Associated With Obesity and Insulin Resistance but Not Type 2 Diabetes in Caucasian Italian Subjects , 2006, Diabetes.

[7]  E. Björnsson,et al.  Clinical characteristics and prognostic markers in disulfiram-induced liver injury. , 2006, Journal of hepatology.

[8]  Paul B Watkins,et al.  Drug‐induced liver injury: Summary of a single topic clinical research conference , 2006, Hepatology.

[9]  A. Hutchinson,et al.  Polymorphisms in Inflammation-related Genes and Risk of Gastric Cancer (Finland) , 2006, Cancer Causes & Control.

[10]  O. Winqvist,et al.  Eosinophil granulocytes are activated during the remission phase of ulcerative colitis , 2005, Gut.

[11]  R. Andrade,et al.  Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. , 2005, Gastroenterology.

[12]  G. Radford-Smith,et al.  TNFα and IL10 SNPs act together to predict disease behaviour in Crohn’s disease , 2005, Journal of Medical Genetics.

[13]  Neil Kaplowitz,et al.  Idiosyncratic drug hepatotoxicity , 2005, Nature Reviews Drug Discovery.

[14]  C. Gutiérrez,et al.  Influence of interleukin-10 genetic polymorphism on survival rates in melanoma patients with advanced disease , 2005, Melanoma research.

[15]  G. Radford-Smith,et al.  TNFalpha and IL10 SNPs act together to predict disease behaviour in Crohn's disease. , 2005, Journal of medical genetics.

[16]  R. Andrade,et al.  HLA class II genotype influences the type of liver injury in drug‐induced idiosyncratic liver disease , 2004, Hepatology.

[17]  G. Alexander,et al.  Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity , 2004, Hepatology.

[18]  S. D'alfonso,et al.  A polymorphic variation in a putative regulation box of the TNFA promoter region , 2004, Immunogenetics.

[19]  P. Costeas,et al.  Cytokine polymorphism frequencies in the Greek Cypriot population. , 2003, European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics.

[20]  W. Hop,et al.  Are cytokine gene polymorphisms related to in vitro cytokine production profiles? , 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[21]  A. Aromaa,et al.  Interleukin‐10 gene promoter region polymorphism is associated with eosinophil count and circulating Immunoglobulin E in adult asthma , 2003, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[22]  D. Weeks,et al.  Interleukin 10 polymorphisms in ankylosing spondylitis , 2003, Genes and Immunity.

[23]  R. Temple,et al.  Safety of newly approved drugs: implications for prescribing. , 2002, JAMA.

[24]  T. Tanimoto,et al.  Serum gamma‐interferon‐inducing factor (IL‐18) and IL‐10 levels in patients with acute hepatitis and fulminant hepatic failure , 2002, Journal of gastroenterology and hepatology.

[25]  L. Guay-Woodford,et al.  Association of cytokine single nucleotide polymorphisms with B7 costimulatory molecules in kidney allograft recipients , 2002, Pediatric transplantation.

[26]  L. Pohl,et al.  Protection against acetaminophen‐induced liver injury and lethality by interleukin 10: Role of inducible nitric oxide synthase , 2002, Hepatology.

[27]  N. Enomoto,et al.  How is the liver primed or sensitized for alcoholic liver disease? , 2001, Alcoholism, clinical and experimental research.

[28]  V. J. Simpson,et al.  No effect of albinism on sedative-hypnotic sensitivity to ethanol and anesthetics. , 2001, Alcoholism, clinical and experimental research.

[29]  I. Yaniv,et al.  Cytokine gene polymorphism in patients with graft-versus-host disease. , 2001, Transplantation proceedings.

[30]  C. Orosz,et al.  EVIDENCE FOR A GENETIC PREDISPOSITION TOWARDS ACUTE REJECTION AFTER KIDNEY AND SIMULTANEOUS KIDNEY-PANCREAS TRANSPLANTATION1 , 2000, Transplantation.

[31]  N. Kaplowitz.  Mechanisms of liver cell injury. , 2000, Journal of hepatology.

[32]  J. Bukh,et al.  The molecular biology of hepatitis C virus. Genotypes and quasispecies. , 1999, Clinics in liver disease.

[33]  D. Purdie,et al.  Interleukin‐10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa , 1999, Hepatology.

[34]  Wei Wu,et al.  Interleukin‐10 controls neutrophilic infiltration, hepatocyte proliferation, and liver fibrosis induced by carbon tetrachloride in mice , 1998, Hepatology.

[35]  R. Westendorp,et al.  Interleukin 10 secretion in relation to human IL-10 locus haplotypes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[36]  H. Nakagawa,et al.  Linkage and association of an interleukin 4 gene polymorphism with atopic dermatitis in Japanese families. , 1998, Journal of medical genetics.

[37]  M. Lazarus,et al.  An investigation of polymorphism in the interleukin-10 gene promoter. , 1997, European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics.

[38]  Kenneth M. Murphy,et al.  Functional diversity of helper T lymphocytes , 1996, Nature.

[39]  M. Klinnert,et al.  Promoter polymorphisms in the chromosome 5 gene cluster in asthma and atopy , 1995, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[40]  C. Wanidworanun,et al.  Predominant role of tumor necrosis factor-alpha in human monocyte IL-10 synthesis. , 1993, Journal of immunology.

[41]  P. Bethwaite,et al.  Effect of tumour associated tissue eosinophilia on survival of women with stage IB carcinoma of the uterine cervix. , 1993, Journal of clinical pathology.

[42]  G. Danan,et al.  Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. , 1993, Journal of clinical epidemiology.

[43]  C. Figdor,et al.  Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression , 1991, The Journal of experimental medicine.

[44]  C. Bénichou.  Criteria of drug-induced liver disorders. Report of an international consensus meeting. , 1990, Journal of hepatology.

[45]  M. Howard.  Interleukins for B lymphocytes , 1983, Survey of immunologic research.